{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T02:12:05Z","timestamp":1770603125016,"version":"3.49.0"},"reference-count":52,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Astra Zeneca Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>This work aimed to investigate the effect of the SGLT2 inhibitor, dapagliflozin (DAPA), on cardiac function and the metabolic and hormonal response to moderate exercise in people with type 2 diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a double-blind, placebo-controlled crossover study with a 4-week washout period. Nine participants were randomly assigned to receive either 4 weeks of DAPA or 4 weeks of placebo. After each treatment, they underwent an exercise protocol with 2 consecutive 10-minute stages at a constant load corresponding to 40% and 70% maximal oxygen consumption (VO2max), coupled with hormonal and metabolic analysis. A blinded transthoracic echocardiogram was performed 3 days later.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the exercise protocol, glucose and lactate were lower (P &amp;lt; .0001 and P &amp;lt; .05, respectively) and \u03b2-hydroxybutyrate (BOBH) and growth hormone (GH) were higher (P &amp;lt; .0005 and P = .01) following DAPA treatment compared to placebo. There was a trend for lower insulin with DAPA. Adrenalin, noradrenalin, and glucagon were not different. Following DAPA participants demonstrated an increased mean peak diastolic mitral annular velocity (e\u2019) in comparison to placebo (P = .03). The indexed left atrial volume and right ventricular e\u201d were reduced following DAPA compared with placebo (P = .045 and P = .042, respectively). Arterial stiffness was not different between treatments (DAPA 9.35 \u00b1 0.60 m\/s; placebo 9.07 \u00b1 0.72 m\/s).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>During exercise, GH may be more important than catecholamines in driving the shift from glucose to fatty acid metabolism by SGLT2 inhibitors. The 4-week crossover design showed changes in cardiac function were rapid in onset and reversible.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac617","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T01:57:58Z","timestamp":1666576678000},"page":"888-896","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8267-6236","authenticated-orcid":false,"given":"Roselle A","family":"Herring","sequence":"first","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Research, Royal Surrey NHS Foundation Trust , Guildford GU2 7XX , UK"},{"name":"Faculty of Health and Medical Sciences, University of Surrey , Guildford GU2 7XH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8577-8289","authenticated-orcid":false,"given":"Iain","family":"Parsons","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Research, Royal Surrey NHS Foundation Trust , Guildford GU2 7XX , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-0447","authenticated-orcid":false,"given":"Fariba","family":"Shojaee-Moradie","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Research, Royal Surrey NHS Foundation Trust , Guildford GU2 7XX , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Stevenage","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Research, Royal Surrey NHS Foundation Trust , Guildford GU2 7XX , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Jackson","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Surrey , Guildford GU2 7XH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0199-2120","authenticated-orcid":false,"given":"Ralph","family":"Manders","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Surrey , Guildford GU2 7XH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-7919","authenticated-orcid":false,"given":"A Margot","family":"Umpleby","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Surrey , Guildford GU2 7XH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7887-809X","authenticated-orcid":false,"given":"Barbara A","family":"Fielding","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Surrey , Guildford GU2 7XH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Davies","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester , Leicester LE1 7RH , UK"},{"name":"NIHR Leicester Biomedical Research Centre , Leicester LE5 4PW , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L","family":"Russell-Jones","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Research, Royal Surrey NHS Foundation Trust , Guildford GU2 7XX , UK"},{"name":"Faculty of Health and Medical Sciences, University of Surrey , Guildford GU2 7XH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"issue":"4","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"issue":"10","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"issue":"9733","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"issue":"11","key":"2023031010311238200_","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.3390\/ijms21217833","article-title":"Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection","volume":"21","author":"Hou","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"15","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"681513","DOI":"10.3389\/fragi.2021.681513","article-title":"Beta-hydroxybutyrate friend or foe for stressed hearts","volume":"2","author":"Chu","year":"2021","journal-title":"Front Aging"},{"issue":"3","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0026-0495(88)90110-2","article-title":"The theoretical bases of indirect calorimetry: a review","volume":"37","author":"Ferrannini","year":"1988","journal-title":"Metab Clin Exp"},{"issue":"1","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"G9","DOI":"10.1530\/ERP-14-0079","article-title":"A minimum dataset for a standard adult transthoracic echocardiogram: a guideline protocol from the British Society of Echocardiography","volume":"2","author":"Wharton","year":"2015","journal-title":"Echo Res Pract"},{"issue":"3","key":"2023031010311238200_","first-page":"351","article-title":"Three methods for evaluation of left atrial volume","volume":"9","author":"Jiamsripong","year":"2008","journal-title":"Eur J Echocardiogr"},{"key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4137\/CMC.S27462","article-title":"Echocardiographic assessment of the right ventricle, from the conventional approach to speckle tracking and three-dimensional imaging, and insights into the \u201cright way\u201d to explore the forgotten chamber","volume":"9","author":"Kossaify","year":"2015","journal-title":"Clin Med Insights Cardiol"},{"issue":"2 Pt 2","key":"2023031010311238200_","first-page":"II19","article-title":"Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods","volume":"9","author":"Devereux","year":"1987","journal-title":"Hypertension"},{"issue":"6","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc21-2043","article-title":"The SGLT2 inhibitor dapagliflozin increases the oxidation of ingested fatty acids to ketones in type 2 diabetes","volume":"45","author":"Herring","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/JOE-19-0385","article-title":"Dapagliflozin restores insulin and growth hormone secretion in obese mice","volume":"245","author":"Huang","year":"2020","journal-title":"J Endocrinol"},{"issue":"6","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1210\/en.2005-1549","article-title":"Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function","volume":"147","author":"Luque","year":"2006","journal-title":"Endocrinology"},{"issue":"5","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"issue":"2","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"issue":"6","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2337\/dc20-2887","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: a randomized, double-blind crossover trial","volume":"44","author":"Op den Kamp","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S2213-8587(14)70033-6","article-title":"Metabolic syndrome: a sympathetic disease?","volume":"3","author":"Schlaich","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 Inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2013.09.002","article-title":"Ketone bodies as signaling metabolites","volume":"25","author":"Newman","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"101395","DOI":"10.1016\/j.redox.2019.101395","article-title":"Ketone bodies, stress response, and redox homeostasis","volume":"29","author":"Rojas-Morales","year":"2020","journal-title":"Redox Biol"},{"issue":"4","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/archinte.1977.03630160061013","article-title":"Hormonal control of ketogenesis. Biochemical considerations","volume":"137","author":"McGarry","year":"1977","journal-title":"Arch Intern Med"},{"issue":"2","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional roles of ketone bodies in fuel metabolism. Signaling, and therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab"},{"issue":"3","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/dmr.5610050306","article-title":"Human ketone body production and utilization studied using tracer techniques: regulation by free fatty acids, insulin, catecholamines, and thyroid hormones","volume":"5","author":"Keller","year":"1989","journal-title":"Diabetes Metab Rev"},{"issue":"8","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"H1060","DOI":"10.1152\/ajpheart.00646.2012","article-title":"Ketone body metabolism and cardiovascular disease","volume":"304","author":"Cotter","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12997\/jla.2022.11.1.1","article-title":"SGLT2 Inhibitors and ketone metabolism in heart failure","volume":"11","author":"Saucedo-Orozco","year":"2022","journal-title":"J Lipid Atheroscler"},{"issue":"11","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/cvr\/cvz045","article-title":"Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency","volume":"115","author":"Ho","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"e124079","DOI":"10.1172\/jci.insight.124079","article-title":"The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense","volume":"4","author":"Horton","year":"2019","journal-title":"JCI Insight"},{"issue":"8","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","article-title":"Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure","volume":"133","author":"Bedi KC","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrcardio.2016.119","article-title":"Heart failure: improvement of LVEF in patients with HF is linked to better prognosis","volume":"13","author":"Huynh","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"158813","DOI":"10.1016\/j.bbalip.2020.158813","article-title":"Ketone metabolism in the failing heart","volume":"1865","author":"Lopaschuk","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2019.11.016","article-title":"High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment","volume":"292","author":"Couselo-Seijas","year":"2020","journal-title":"Atherosclerosis"},{"key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"592233","DOI":"10.3389\/fcvm.2020.592233","article-title":"Empagliflozin decreases lactate generation in an NHE-1 dependent fashion and increases \u03b1-ketoglutarate synthesis from palmitate in type II diabetic mouse hearts","volume":"7","author":"Zhang","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fphys.2013.00152","article-title":"Mitochondrial NHE1: a newly identified target to prevent heart disease","volume":"4","author":"Alvarez","year":"2013","journal-title":"Front Physiol"},{"issue":"4","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1249\/01.mss.0000210203.10200.12","article-title":"Left ventricular function immediately following prolonged exercise: a meta-analysis","volume":"38","author":"Middleton","year":"2006","journal-title":"Med Sci Sports Exerc"},{"issue":"4","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.euje.2003.10.001","article-title":"Effects of the reduction of preload on left and right ventricular myocardial velocities analyzed by Doppler tissue echocardiography in healthy subjects","volume":"5","author":"Pel\u00e0","year":"2004","journal-title":"Eur J Echocardiogr"},{"issue":"1","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-020-01175-5","article-title":"Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study","volume":"20","author":"Rau","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes. Mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","article-title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","volume":"524","author":"Chowdhury","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1253\/circj.CJ-20-0341","article-title":"Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients\u2014a randomized controlled trial","volume":"84","author":"Kayano","year":"2020","journal-title":"Circ J"},{"issue":"17","key":"2023031010311238200_","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac617\/46855444\/dgac617.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/4\/888\/49499380\/dgac617.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/4\/888\/49499380\/dgac617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T12:13:33Z","timestamp":1701260013000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/4\/888\/6770121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,24]]},"published-print":{"date-parts":[[2023,3,10]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac617","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,10,24]]}}}